CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Dexamethasone Implant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01951066
NCT01951066Phase 2Completed
CompareCT.gov

Diabetic Macular Edema Treated With Ozurdex (DMEO)

Johns Hopkins University·interventional·Posted Sep 26, 2013·Updated Sep 29, 2016

In Brief

A Phase 2 clinical trial evaluating Dexamethasone Implant and Anti-VEGF injection for Diabetic Macular Edema. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To measure various pro-permeability factors in the aqueous humor of patients with persistent/recurrent diabetic macular edema

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 26, 2013
Enrollment StartOct 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.8 years ago

Interventions

Dexamethasone Implantdrug

Patients will receive a single injection of a dexmethasone implant

Anti-VEGF injectiondrug

Patients will receive PRN injections of an anti-VEGF agent